Alzheimer's disease: drug discovery
Alzheimer’s disease is the most common cause of age-related dementia. Alzheimer’s disease presents with irreversible cognitive decline, which commences as insidious short-term memory dysfunction and gradually spreads to other cognitive domains, rendering patients mute and non-ambulatory after 10-15...
Gespeichert in:
Weitere Verfasser: | |
---|---|
Format: | Elektronisch E-Book |
Sprache: | English |
Veröffentlicht: |
Brisbane, Australia
Exon Publications
December 2020
|
Schlagworte: | |
Online-Zugang: | Volltext Volltext |
Zusammenfassung: | Alzheimer’s disease is the most common cause of age-related dementia. Alzheimer’s disease presents with irreversible cognitive decline, which commences as insidious short-term memory dysfunction and gradually spreads to other cognitive domains, rendering patients mute and non-ambulatory after 10-15 years of progressive course. Unfortunately, there are neither effective preventive measures nor efficacious treatments available for this devastating disease. Such a situation undoubtedly calls for the diversification of druggable targets for Alzheimer’s disease and a search for poly-targets or drug combination therapeutic strategies. Contributed by an assembly of clinicians and translational and basic research scientists, this book intends to provide an overview of the current state and future perspectives of Alzheimer’s disease drug discovery. It covers the underlying pathogenic mechanisms of Alzheimer’s disease and provides a review of Aβ amyloid- and τ protein-targeted immunotherapies, and peptide inhibitors for anti-Aβ amyloidosis. In addition, it also examines therapeutic potentials of various Alzheimer’s disease drug targets such as brain metal homeostasis, protein kinase C, the blood-brain barrier, epigenetic therapies, as well as discusses chimeric conjugates, multifunctional ligands, and natural products as interventional approaches. This book will be valuable to healthcare professionals caring for patients, researchers and interested readers as it will provoke thoughts about identifying novel and more efficacious therapeutic agents for Alzheimer’s disease and related dementias. |
Beschreibung: | 1 Online-Ressource (xiv, 229 Seiten) |
ISBN: | 9780645001709 |
DOI: | 10.36255/exonpublications.alzheimersdisease.2020 |
Internformat
MARC
LEADER | 00000nam a22000001c 4500 | ||
---|---|---|---|
001 | BV048446665 | ||
003 | DE-604 | ||
007 | cr|uuu---uuuuu | ||
008 | 220829s2020 xx o|||| 00||| eng d | ||
020 | |a 9780645001709 |9 978-0-6450017-0-9 | ||
024 | 7 | |a 10.36255/exonpublications.alzheimersdisease.2020 |2 doi | |
035 | |a (OCoLC)1344268367 | ||
035 | |a (DE-599)HEB497463865 | ||
040 | |a DE-604 |b ger |e rda | ||
041 | 0 | |a eng | |
049 | |a DE-12 |a DE-210 |a DE-521 |a DE-1102 |a DE-1046 |a DE-1028 |a DE-1050 |a DE-573 |a DE-M347 |a DE-92 |a DE-1051 |a DE-898 |a DE-859 |a DE-860 |a DE-1049 |a DE-861 |a DE-863 |a DE-862 |a DE-Re13 |a DE-Y3 |a DE-255 |a DE-Y7 |a DE-Y2 |a DE-70 |a DE-2174 |a DE-127 |a DE-22 |a DE-155 |a DE-91 |a DE-384 |a DE-473 |a DE-19 |a DE-355 |a DE-703 |a DE-20 |a DE-706 |a DE-824 |a DE-29 |a DE-739 | ||
084 | |a YG 4015 |0 (DE-625)153494:12921 |2 rvk | ||
245 | 1 | 0 | |a Alzheimer's disease |b drug discovery |c edited by Xudong Huang, PhD |
264 | 1 | |a Brisbane, Australia |b Exon Publications |c December 2020 | |
264 | 2 | |a The Hague |b OAPEN FOUNDATION | |
300 | |a 1 Online-Ressource (xiv, 229 Seiten) | ||
336 | |b txt |2 rdacontent | ||
337 | |b c |2 rdamedia | ||
338 | |b cr |2 rdacarrier | ||
520 | 3 | |a Alzheimer’s disease is the most common cause of age-related dementia. Alzheimer’s disease presents with irreversible cognitive decline, which commences as insidious short-term memory dysfunction and gradually spreads to other cognitive domains, rendering patients mute and non-ambulatory after 10-15 years of progressive course. Unfortunately, there are neither effective preventive measures nor efficacious treatments available for this devastating disease. Such a situation undoubtedly calls for the diversification of druggable targets for Alzheimer’s disease and a search for poly-targets or drug combination therapeutic strategies. Contributed by an assembly of clinicians and translational and basic research scientists, this book intends to provide an overview of the current state and future perspectives of Alzheimer’s disease drug discovery. It covers the underlying pathogenic mechanisms of Alzheimer’s disease and provides a review of Aβ amyloid- and τ protein-targeted immunotherapies, and peptide inhibitors for anti-Aβ amyloidosis. In addition, it also examines therapeutic potentials of various Alzheimer’s disease drug targets such as brain metal homeostasis, protein kinase C, the blood-brain barrier, epigenetic therapies, as well as discusses chimeric conjugates, multifunctional ligands, and natural products as interventional approaches. This book will be valuable to healthcare professionals caring for patients, researchers and interested readers as it will provoke thoughts about identifying novel and more efficacious therapeutic agents for Alzheimer’s disease and related dementias. | |
650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Alzheimerkrankheit |0 (DE-588)4112510-1 |2 gnd |9 rswk-swf |
653 | |a Etiology of Alzheimer’s Disease; Epidemiology of Alzheimer’s Disease; Neuropathology of Alzheimer’s Disease; Pathogenesis of Alzheimer’s Disease; Immunotherapy for Alzheimer’s Disease; Amyloid β-Targeted Inhibitory Peptides for Alzheimer’s Disease; Tau Protein-Targeted Therapies in Alzheimer’s Disease; Targeting Metal Homeostasis for Alzheimer’s Disease; Insulin-Resistant in Alzheimer’s Disease; Blood–Brain Barrier in Alzheimer’s Disease; Epigenetic Modifications in Alzheimer’s Disease; Chimeric Conjugates for Alzheimer’s Disease; Multifunctional Ligand Approach for Alzheimer’s Disease; Natural Products for Alzheimer’s Disease | ||
655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
689 | 0 | 0 | |a Alzheimerkrankheit |0 (DE-588)4112510-1 |D s |
689 | 0 | 1 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
689 | 0 | |5 DE-604 | |
700 | 1 | |a Huang, Xudong |0 (DE-588)1111530750 |4 edt | |
856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/81835.3 |x Verlag |z kostenfrei |3 Volltext |
856 | 4 | 0 | |u https://doi.org/10.36255/exonpublications.alzheimersdisease.2020 |x Verlag |z kostenfrei |3 Volltext |
912 | |a ZDB-94-OAB | ||
943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-033824887 |
Datensatz im Suchindex
_version_ | 1824555454659821569 |
---|---|
adam_text | |
adam_txt | |
any_adam_object | |
any_adam_object_boolean | |
author2 | Huang, Xudong |
author2_role | edt |
author2_variant | x h xh |
author_GND | (DE-588)1111530750 |
author_facet | Huang, Xudong |
building | Verbundindex |
bvnumber | BV048446665 |
classification_rvk | YG 4015 |
collection | ZDB-94-OAB |
ctrlnum | (OCoLC)1344268367 (DE-599)HEB497463865 |
discipline | Medizin |
discipline_str_mv | Medizin |
doi_str_mv | 10.36255/exonpublications.alzheimersdisease.2020 |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a22000001c 4500</leader><controlfield tag="001">BV048446665</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220829s2020 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780645001709</subfield><subfield code="9">978-0-6450017-0-9</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.36255/exonpublications.alzheimersdisease.2020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1344268367</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)HEB497463865</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-210</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-1102</subfield><subfield code="a">DE-1046</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-1050</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-M347</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-1051</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-859</subfield><subfield code="a">DE-860</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-863</subfield><subfield code="a">DE-862</subfield><subfield code="a">DE-Re13</subfield><subfield code="a">DE-Y3</subfield><subfield code="a">DE-255</subfield><subfield code="a">DE-Y7</subfield><subfield code="a">DE-Y2</subfield><subfield code="a">DE-70</subfield><subfield code="a">DE-2174</subfield><subfield code="a">DE-127</subfield><subfield code="a">DE-22</subfield><subfield code="a">DE-155</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-384</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-703</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-706</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YG 4015</subfield><subfield code="0">(DE-625)153494:12921</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Alzheimer's disease</subfield><subfield code="b">drug discovery</subfield><subfield code="c">edited by Xudong Huang, PhD</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Brisbane, Australia</subfield><subfield code="b">Exon Publications</subfield><subfield code="c">December 2020</subfield></datafield><datafield tag="264" ind1=" " ind2="2"><subfield code="a">The Hague</subfield><subfield code="b">OAPEN FOUNDATION</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xiv, 229 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">Alzheimer’s disease is the most common cause of age-related dementia. Alzheimer’s disease presents with irreversible cognitive decline, which commences as insidious short-term memory dysfunction and gradually spreads to other cognitive domains, rendering patients mute and non-ambulatory after 10-15 years of progressive course. Unfortunately, there are neither effective preventive measures nor efficacious treatments available for this devastating disease. Such a situation undoubtedly calls for the diversification of druggable targets for Alzheimer’s disease and a search for poly-targets or drug combination therapeutic strategies. Contributed by an assembly of clinicians and translational and basic research scientists, this book intends to provide an overview of the current state and future perspectives of Alzheimer’s disease drug discovery. It covers the underlying pathogenic mechanisms of Alzheimer’s disease and provides a review of Aβ amyloid- and τ protein-targeted immunotherapies, and peptide inhibitors for anti-Aβ amyloidosis. In addition, it also examines therapeutic potentials of various Alzheimer’s disease drug targets such as brain metal homeostasis, protein kinase C, the blood-brain barrier, epigenetic therapies, as well as discusses chimeric conjugates, multifunctional ligands, and natural products as interventional approaches. This book will be valuable to healthcare professionals caring for patients, researchers and interested readers as it will provoke thoughts about identifying novel and more efficacious therapeutic agents for Alzheimer’s disease and related dementias.</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Alzheimerkrankheit</subfield><subfield code="0">(DE-588)4112510-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Etiology of Alzheimer’s Disease; Epidemiology of Alzheimer’s Disease; Neuropathology of Alzheimer’s Disease; Pathogenesis of Alzheimer’s Disease; Immunotherapy for Alzheimer’s Disease; Amyloid β-Targeted Inhibitory Peptides for Alzheimer’s Disease; Tau Protein-Targeted Therapies in Alzheimer’s Disease; Targeting Metal Homeostasis for Alzheimer’s Disease; Insulin-Resistant in Alzheimer’s Disease; Blood–Brain Barrier in Alzheimer’s Disease; Epigenetic Modifications in Alzheimer’s Disease; Chimeric Conjugates for Alzheimer’s Disease; Multifunctional Ligand Approach for Alzheimer’s Disease; Natural Products for Alzheimer’s Disease</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Alzheimerkrankheit</subfield><subfield code="0">(DE-588)4112510-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Xudong</subfield><subfield code="0">(DE-588)1111530750</subfield><subfield code="4">edt</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://directory.doabooks.org/handle/20.500.12854/81835.3</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.36255/exonpublications.alzheimersdisease.2020</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-94-OAB</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033824887</subfield></datafield></record></collection> |
genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
genre_facet | Aufsatzsammlung |
id | DE-604.BV048446665 |
illustrated | Not Illustrated |
index_date | 2024-07-03T20:29:24Z |
indexdate | 2025-02-20T07:07:55Z |
institution | BVB |
isbn | 9780645001709 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033824887 |
oclc_num | 1344268367 |
open_access_boolean | 1 |
owner | DE-12 DE-210 DE-521 DE-1102 DE-1046 DE-1028 DE-1050 DE-573 DE-M347 DE-92 DE-1051 DE-898 DE-BY-UBR DE-859 DE-860 DE-1049 DE-861 DE-863 DE-BY-FWS DE-862 DE-BY-FWS DE-Re13 DE-BY-UBR DE-Y3 DE-255 DE-Y7 DE-Y2 DE-70 DE-2174 DE-127 DE-22 DE-BY-UBG DE-155 DE-BY-UBR DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-703 DE-20 DE-706 DE-824 DE-29 DE-739 |
owner_facet | DE-12 DE-210 DE-521 DE-1102 DE-1046 DE-1028 DE-1050 DE-573 DE-M347 DE-92 DE-1051 DE-898 DE-BY-UBR DE-859 DE-860 DE-1049 DE-861 DE-863 DE-BY-FWS DE-862 DE-BY-FWS DE-Re13 DE-BY-UBR DE-Y3 DE-255 DE-Y7 DE-Y2 DE-70 DE-2174 DE-127 DE-22 DE-BY-UBG DE-155 DE-BY-UBR DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-703 DE-20 DE-706 DE-824 DE-29 DE-739 |
physical | 1 Online-Ressource (xiv, 229 Seiten) |
psigel | ZDB-94-OAB |
publishDate | 2020 |
publishDateSearch | 2020 |
publishDateSort | 2020 |
publisher | Exon Publications |
record_format | marc |
spellingShingle | Alzheimer's disease drug discovery Arzneimittel (DE-588)4003115-9 gnd Alzheimerkrankheit (DE-588)4112510-1 gnd |
subject_GND | (DE-588)4003115-9 (DE-588)4112510-1 (DE-588)4143413-4 |
title | Alzheimer's disease drug discovery |
title_auth | Alzheimer's disease drug discovery |
title_exact_search | Alzheimer's disease drug discovery |
title_exact_search_txtP | Alzheimer's disease drug discovery |
title_full | Alzheimer's disease drug discovery edited by Xudong Huang, PhD |
title_fullStr | Alzheimer's disease drug discovery edited by Xudong Huang, PhD |
title_full_unstemmed | Alzheimer's disease drug discovery edited by Xudong Huang, PhD |
title_short | Alzheimer's disease |
title_sort | alzheimer s disease drug discovery |
title_sub | drug discovery |
topic | Arzneimittel (DE-588)4003115-9 gnd Alzheimerkrankheit (DE-588)4112510-1 gnd |
topic_facet | Arzneimittel Alzheimerkrankheit Aufsatzsammlung |
url | https://directory.doabooks.org/handle/20.500.12854/81835.3 https://doi.org/10.36255/exonpublications.alzheimersdisease.2020 |
work_keys_str_mv | AT huangxudong alzheimersdiseasedrugdiscovery |